Another study by Bujalance et al. (2020) reported that empagliflozin users exhibited a reduced risk of vascular dementia, highlighting the neuroprotective potential of SGLT-2 inhibitors across different dementia subtypes [54]. The gene discussed is SLC5A2; the disease is vascular dementia.